

Journal of Visualized Experiments

Core/shell printing scaffolds for tissue engineering of tubular structures

--Manuscript Draft--

| | |
|------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Article Type: | Invited Methods Article - JoVE Produced Video |
| Manuscript Number: | JoVE59951R2 |
| Full Title: | Core/shell printing scaffolds for tissue engineering of tubular structures |
| Keywords: | Core/shell; coaxial; bioprinting; Bioengineering; tissue engineering; vascularization |
| Corresponding Author: | Bostjan Vihar Institute IRNAS Maribor, Styria SLOVENIA |
| Corresponding Author's Institution: | Institute IRNAS |
| Corresponding Author E-Mail: | bostjan@irnas.eu |
| Order of Authors: | Marko Milojević Bostjan Vihar Luka Banović Mihael Miško Lidija Gradišnik Tanja Zidarič Uroš Maver |
| Additional Information: | |
| Question | Response |
| Please indicate whether this article will be Standard Access or Open Access. | Standard Access (US\$2,400) |
| Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations. | Maribor, Slovenia, EU |

TITLE:

Core/Shell Printing Scaffolds for Tissue Engineering of Tubular Structures

AUTHORS AND AFFILIATIONS:

Marko Milojević¹, Boštjan Vihar^{1,2}, Luka Banović², Mihael Miško², Lidija Gradišnik¹, Tanja Zidarič¹, Uroš Maver^{1,3}

¹Institute of Biomedical Sciences, Faculty of Medicine, University of Maribor, Maribor, Slovenia

²Institute for Development of Advanced Applied Systems (IRNAS), Maribor, Slovenia

³Department of Pharmacology, Faculty of Medicine, University of Maribor, Maribor, Slovenia

Corresponding Authors:

Marko Milojević (marko.milojevic1@um.si)

Boštjan Vihar (bostjan.vihar@um.si)

KEYWORDS:

core/shell, coaxial, bioprinting, bioengineering, tissue engineering, CMC, alginate, tubular, tissue, engineering, vascularization

SUMMARY:

Presented here is a simple-to-use, core/shell, three-dimensional bioprinting set-up for one-step fabrication of hollow scaffolds, suitable for tissue engineering of vascular and other tubular structures.

ABSTRACT:

Three-dimensional (3D) printing of core/shell filaments allows direct fabrication of channel structures with a stable shell that is cross-linked at the interface with a liquid core. The latter is removed post-printing, leaving behind a hollow tube. Integrating an additive manufacturing technique (like the one described here with tailor-made [bio]inks, which structurally and biochemically mimic the native extracellular matrix [ECM]) is an important step towards advanced tissue engineering. However, precise fabrication of well-defined structures requires tailored fabrication strategies optimized for the material in use. Therefore, it is sensible to begin with a set-up that is customizable, simple-to-use, and compatible with a broad spectrum of materials and applications. This work presents an easy-to-manufacture core/shell nozzle with luer-compatibility to explore core/shell printing of woodpile structures, tested with a well-defined, alginate-based scaffold material formulation.

INTRODUCTION:

Arguably, the ultimate objective of tissue engineering (TE) is to produce functional tissues or organs in vitro, which can be used to regenerate or replace injured or diseased parts of the human body¹⁻³. Current research in tissue engineering (TE) is focused on individual aspects of the field (scaffolding materials, fabrication procedures, cell sources, etc.)^{4,5}, as well as developing simple in vitro models of tissues and organs that mimic fundamental aspects of

their in vivo counterparts. Such models are already useful for many applications, such as drug screening and toxicity studies, especially in cases where conventional 2D cell cultures fail to mimic the dynamic responses of the native tissues⁶⁻⁹. Three-dimensional in vitro models are usually constructed by combining cells¹⁰, physico-chemical cues¹¹, and biologically active molecules^{12,13} on scaffolds, which are obtained from decellularized tissues or constructed *de novo* from biological or biocompatible materials¹⁴⁻¹⁸.

It is crucial that scaffolds recapitulate the complex 3D microarchitecture and hierarchical structure of the native tissues to enable functionality of the engineered tissues, representative of in vivo tissues¹⁹. Despite the significant technological advancement in TE, development of physiologically relevant artificial tissue constructs remains a challenge. Thick tissues (>200 µm in thickness) are especially problematic, due to limitations such as oxygen and nutrient diffusion²⁰. Progress towards larger tissue constructs has been made; however, the required high proximity of cells to blood vessels in order to transport oxygen and nutrients and promote waste removal must be recapitulated. Vascularization of tissues (or alternatively, fabrication of interconnected 3D vascular networks within tissue constructs) plays a critical role in maintaining cell viability and promoting functions of in vitro engineered tissues, which is more difficult for models in prolonged experiments^{21,22}. Furthermore, the required resolution, structural integrity, and simultaneous biocompatibility has yet to be achieved²³.

Several TE approaches have been proposed in an attempt to construct blood vessel-like structures and facilitate vascularization in vitro. Some examples include seeding endothelial cells (also co-cultured with other cells types such as fibroblasts) that self-assemble to generate microvascular networks²⁴, use of vascular progenitor cells and pericytes that promote endothelial cell growth^{21,25}, the delivery of angiogenic growth factors that induce vascularization^{20,26}, using cell sheet technology that allows for control over vascular layering²⁰, and fabrication of highly porous scaffold structures that promote angiogenesis²⁷. The mentioned approaches focus on angiogenesis induction, which generally requires considerable amounts of additional growth factors (e.g., VEGF) and time to form. However, the biggest drawbacks are their limited reproducibility and restricted spatial control over vascular patterning, usually resulting in a random vasculature distribution within the tissue construct that does not necessarily facilitate perfusion.

Additive manufacturing (AM, such as 3D bioprinting) is increasingly involved in the fabrication of 3D constructs using biological or biocompatible materials to create scaffolds suitable for TE. Several AM approaches are being used and developed in parallel (e.g., ink jet- and microextrusion-based methods, different types of lithographic techniques) to produce scaffolds that mimic native tissues in their architecture, biochemistry, and functionality. The individual techniques exhibit certain advantages and disadvantages²⁸, which is why various modifications being explored (e.g., micro-patterning, induced angiogenesis, etc.) to increase the extent to which large, complex, and stable vascular networks can be fabricated^{22,29,30}.

Among these, extrusion bioprinting is the most commonly used method, especially due to the broad range of compatible materials (a generally cell-friendly process^{28,31,32}) as well as exceptional versatility in terms of applications (e.g., embedded and sacrificial printing^{23,33}, fabrication of hollow structures^{34,35}, etc.). The main challenges preoccupying present studies

include the transfer from 2D to 3D structures, formation of a dense network of hollow tubes with high spatial resolution, and overall mechanical integrity and shape fidelity during fluid flow in cell culture conditions³⁰.

The most straightforward approach to perfusable tissue is the fabrication of an interconnected network of channels within the construct. The creation of such perfusable channels within a tissue scaffold is expected to solve many of the aforementioned problems, as it immediately allows for nutrient and oxygen diffusion while removing waste products. Therefore, the potential formation of necrotic regions within the construct is avoided³⁶. Such channels may additionally be seeded with endothelial cells (ECs) and serve as artificial blood vessels in 3D tissue models³⁷. In the most elementary sense, a vessel can consist of a hollow channel, soft layer of ECs, and stiff shell. Recently, 3D extrusion of two different materials in a core/shell fashion utilizing co-axial needles for extrusion has gained much interest³⁸⁻⁴¹, as it allows for fabrication of hollow tubes.

Similar to conventional microextrusion 3D printing, core/shell printing is performed with a co-axial nozzle (e.g., two needles with different diameters aligned on the same axis in a manner, so that the wider needle encloses the narrower one). Thus, two materials can be extruded simultaneously, with one as the central filament or “inner” core and a second as the “outer” shell⁴¹. To date, co-axial bioprinting has been utilized to fabricate structures with solid⁴², core/shell⁴³, and hollow strands^{40,44}; however, the materials used have not been optimized for both optimal cell viability and mechanical robustness of the printed constructs. As mentioned, the technique provides the possibility to combine biomaterials with different mechanical properties, in which the stiffer one supports the softer one. More importantly, if the scaffold material (e.g., alginate, carboxymethyl cellulose) is extruded as the shell, while the core composed of the cross-linking agent (e.g., calcium chloride) is dispensed from the inner capillary then rinsed out post-printing, it is possible to fabricate a continuous hollow tube in a single step⁴⁵.

With this in mind, a simple and repeatable one-step method was developed to build well-defined and perfusable scaffolds for the engineering of vascular structures and other tubular tissues. To develop a cost-effective technology, fabrication should ideally be a single-step process. Therefore, a core/shell set-up was adapted and integrated into the 3D bioprinter. The basic design consists of a central nozzle made of metal to avoid deformation during injection, around which a second nozzle of a larger diameter is placed. Such a co-axial nozzle set-up allows for co-extrusion of the two flows and immediate cross-linking of the extruded hydrogel channel. This enables direct fabrication of multilayered hollow filaments, while subsequent cross-linking with higher concentrations of calcium chloride (CaCl₂) ensure more permanent stabilization from the outside.

As such, this method allows for concurrent printing of scaffolds and microchannels, in which the hollow hydrogel filaments serve as a scaffold to support the mechanical integrity of 3D constructs and simultaneously act as built-in microchannels to deliver nutrients for cell growth. This protocol provides a detailed procedure of the core/shell 3D bioprinting strategy based on use of a custom-made co-axial nozzle in which hydrogel 3D structures with built-in channels are fabricated by controlling cross-linking to produce hollow filaments, which remain perfusable during cell culture.

The 3D printing set-up used in this work is configured as previously described by Banović and Vihar⁴⁶ and can be divided into three main components: A) a three-axis CNC mechanical set-up with 50 μm positioning accuracy in the X, Y, and Z directions; B) two extruders, adapted for disposable, 5 mL luer-lock syringes, with 1.2 μL voxel resolution; and C) controlling electronics and software.

To facilitate core/shell printing, an appropriate nozzle was developed that can be mounted on one of the extruders (primary extruder, printing the core) and is compatible with G27 blunt-end needles. It also has luer-lock compatibility to connect with the second extruder (printing the shell). The first prototypes were fabricated by inserting a blunt-end G27 needle (inner diameter = 210 μm , outer diameter = 410 μm) into either a G21 needle (inner diameter = 510 μm , outer diameter = 820 μm) or G20 conical tip (inner diameter = 600 μm), then inserting a secondary needle laterally to supply the shell material. However, due to slight bending of the needle shaft, it is not possible to produce a nozzle tip with concentric alignment of the inner and outer needles.

To solve this issue, a new nozzle design was devised that fulfilled the following criteria: 1) it can be manufactured using a 3-axis CNC mill, 2) it can be made from various materials (high performance plastics, such as PEEK or metals), 3) it has luer-lock compatibility for applying shell material, and 4) is compatible for a G27 blunt-end needle and holds it in place at two positions to align the tip with the central axis. A schematic of the nozzle prototype is shown in **Figure 1**.

PROTOCOL:

1. Preparation of hydrogels and cross-linking solutions

1.1. Briefly, by vigorously mixing, dissolve ALG and CMC powders in ultra-pure water to obtain a total 3 wt% ALG and 3 wt% CMC solution.

NOTE: In this work, 5 mL syringes are used for printing; thus, the final amount of material is adjusted to that volume. However, for other extrusion cartridges and printed sample sizes, the amount of prepared material should be scaled accordingly.

1.2. Add 1.5 wt% cellulose nanofibers to the ALG-CMC mixture for additional mechanical reinforcement to reach the desired viscosity, suitable for printing.

1.3. Agitate the hydrogel suspension until homogeneous using an overhead mixer.

NOTE: No fibers or bubbles should be present in the hydrogel.

1.4. Prepare 10 mL of 100 mM calcium chloride (CaCl_2) solution in ultra-pure water, which is used as the primary cross-linking solution for printing.

1.5. Prepare 10 mL of 5 wt.% CaCl_2 solution in ultra-pure water, which is used as a secondary cross-linking solution in post processing of scaffolds.

NOTE: Generally, all hydrogel formulations, which are suitable for immediate chemical cross-linking, allow for one-step fabrication of hollow tubes and can be used with this type of core/shell set-up. The printing and cross-linking mechanisms need to be optimized accordingly. Viscosity of the hydrogel will vary depending on the desired composition; however, it can be adjusted with polymer concentrations and the addition of thickening agents (e.g., nanofibers). The ideal viscosity for 3D printing of stable structures is high enough for the extruded filament to retain its shape and for the scaffold to hold its own weight before cross-linking.

2. Core/shell printing of perfusable scaffolds

2.1. Prior to printing, sterilize the bioprinter by spraying 70% ethanol thoroughly and expose it to UV light for 1 h.

2.2. Turn on the bioprinter and run the controlling software, which comes in a bundle with the 3D printer.

2.3. Perform the homing procedure by pressing the **Home** icon.

2.4. Using the toolbar command **File | Import G-Code**, import the generated scaffold g-code.

2.5. Transfer the hydrogel to a sterile 5 mL syringe and place it in one of the extruder mounts of the 3D printer. Via the luer-lock and a short tube, connect it to side luer input of the core/shell nozzle.

2.6. Transfer the cross-linking solution (100 mM CaCl_2) to another sterile 5 mL syringe with an attached G27 blunt-end needle and insert it into the top needle holder of the core/shell nozzle. The inner needle should slightly protrude (~1 mm) from the outer core/shell nozzle. Adjust the alignment manually. Insert the second syringe in the extrusion mount.

2.7. To correctly insert the syringes into the mounts (set-up shown in **Figure 2**), manually control both extrusion mounts by clicking the **A and B** and **Up and Down** arrows.

2.8. Before the printing starts, separately extrude the hydrogel and the cross-linking solution to clear all excess air bubbles in the core/shell nozzle and ensure a continuous hydrogel flow.

2.9. Using the **Z** and **Up and Down** arrows, manually adjust the distance between the nozzle and printing substrate. It is recommended to use a flat, glass-printing substrate, which has good adhesion. The extrusion nozzle should not be in contact with the substrate to allow for uninterrupted flow of the hydrogel. The optimal distance between the nozzle and substrate (layer height) is typically the same as the width of the outer nozzle diameter, but it is adjusted to the material used and individual printing parameters. Adjust the starting printing height according to individual needs.

2.10. Press the **Play** button to start the printing process.

NOTE: It is recommended to include the printing of a skirt (**Figure 3**) surrounding the scaffold to ensure the laying of a homogenous hollow filament before printing of the actual scaffold starts. To achieve optimal hydrogel flow with the intention to print optimal scaffolds, vary formulation composition, cross-linking solution composition, and printing parameters (i.e., printing speed, extrusion pressure, printing temperature, distance between the substrate and extrusion nozzle, etc.).

2.11. After printing, carefully remove the substrate with the printed scaffold and pour the secondary cross-linking solution (5 wt.% CaCl_2) over the entire scaffold to ensure the cross-linkage over the entire scaffold. Incubate for 1 min at room temperature (RT).

NOTE: Make sure that the entire scaffold is submerged in the cross-linking solution. This step is crucial for achieving desired strength properties of the scaffold but will vary depending on the material and cross-linking method used.

2.12. Using a scalpel manually cut the excess skirt material.

2.13. Sterilize the scaffolds under an UV light for 30 min. Carefully flip the scaffold and repeat the sterilization process.

2.14. Carefully detach the scaffold from the substrate by gently pulling it sideways. If the scaffold adheres strongly to the substrate, separate it by inserting a sharp edge between them.

2.15. Transfer the scaffold into a colorless cell culture media (DMEM supplemented with 5 wt.% FBS, 100 U/mL penicillin and 1 mg/mL streptomycin), and incubate them at 37 °C in an atmosphere containing 5 wt.% CO_2 for at least 24 h.

3. Preparation of endothelial cells and live/dead assay solution

3.1. For cell culturing, prepare the advanced DMEM cell culture medium with added phenol red and supplement it with 5 wt.% FBS and 2 mM L-glutamine. Add 100 U/mL penicillin and 1 mg/mL streptomycin.

3.2. Initiate the human umbilical vein endothelial cell (HUVEC) line and passage them in accordance with HUVEC culturing protocols as described⁴⁷.

NOTE: It is recommended to culture the cells in cell culture media with added phenol red for simple visualization during injection of the cells into white translucent scaffolds as described below.

3.3. For cell counting, pipette 100 μL of cells suspended in cell culture media and stain them with 900 μL of 0.1 wt.% trypan blue solution.

3.4. Use an automated cell counter or manual hemocytometer to count and obtain the estimated number of cells in suspension.

3.5. For the live/dead assay, prepare a solution of 4 mM Calcein-AM and 2 mM propidium iodide in sterile PBS.

NOTE: The live/dead solution should be prepared directly before conducting the assay.

4. Transferring cells into scaffolds

4.1. Remove the scaffolds from cell culture media and transfer them into a sufficiently large glass Petri dish.

4.2. Immediately before injecting the cells into the scaffolds, dissociate the HUVECs from the flasks using treatment by 0.25 wt.% trypsin.

4.2.1. Briefly, dispose cell culture media and incubate the cells with 0.25 wt.% trypsin (~2 mL) for 5 min at 37 °C.

4.2.2. After incubation add ~3 mL of cell culture media to the trypsinized cells and transfer all detached cells to a centrifuge tube.

4.2.3. Centrifuge the cells at 200 x g for 5 min and dispose of the supernatant.

4.2.4. Resuspend the cells in fresh cell culture media.

4.3. Count the cells as described previously. Adjust the total cell concentration according to individual needs. In this work, a starting concentration of 340,000 cells/mL is used.

4.4. Resuspend the cells in a sterile syringe with an attached blunt G27 needle.

4.5. Find an entry point and start carefully injecting cells into the scaffolds. The cell suspension flow through a translucent scaffold should be visible. Make sure that the entire scaffold fills up with cell suspension.

4.6. Submerge the scaffolds in cell culture media and incubate them at 37 °C in an atmosphere containing 5 wt.% CO₂ for up to 10 days.

4.7. Replenish the cell culture media according to experimental needs.

5. Live/dead assay and cell imaging

5.1. After incubation, rinse the scaffolds with PBS.

5.2. With a blunt-end needle, carefully inject the previously prepared live/dead solution (4 mM calcein-AM and 2 mM propidium iodide in PBS) into the scaffolds and incubate them in

PBS for 30 min at 37 °C. Make sure that the solution flows through the length of the entire scaffold.

5.3. Rinse the scaffolds with PBS.

5.4. Carefully transfer the scaffolds to a glass slide.

5.5. Observe the dyed cells directly in the scaffolds under a fluorescence microscope.

NOTE: Viable cells produce green fluorescence and dead cells emit red fluorescence light.

REPRESENTATIVE RESULTS:

The aim of this work was to develop an easy-to-manufacture core/shell nozzle with luer-compatibility for core/shell printing of woodpile structures. In addition, a straightforward and repeatable one-step printing protocol was described, which is simple to modify and accommodates a broad range of materials and different chemical cross-linking mechanisms to build well-defined and perfusable scaffolds for engineering of vascular and other tubular tissue structures.

Core/shell nozzle

The nozzle is composed of a G27 blunt-end needle (for printing the inner axial filament) and the nozzle body, which holds the needle in place and creates an outer nozzle for the shell filament with a connection port for material input. A schematic is shown in **Figure 1**. Two 5 mL syringes, which are placed into the individual extruders and provide the core and shell materials. Tubing connects the nozzle body with the syringe, providing the shell material.

The complete assembly of the core/shell nozzle and syringe set-up is shown in **Figure 2**. The first functional prototype of the nozzle body was manufactured by CNC milling a block of polyoxymethylene (POM). Compatibility and sealing between the element, a G27 needle and tubing was tested by installing into Vitaprint. No leakage of the shell material was observed in the nozzle, luer-lock connector, or between body and needle. The nozzle body fits tightly with the needle hub (luer connector), ensuring synchronized motion of the whole nozzle with the extruder.

Scaffold building

The most straightforward approach to fabricating scaffolds is by depositing materials layer by layer where printing direction is changed every consecutive layer, typically at an angle of 90°. Due to the visco-elastic and hygroscopic properties of the hydrogels, retaining shape fidelity of the printed structures remains challenging. The main purpose of this protocol section is 3D printing of perfusable core/shell scaffolds using two polymers, which have previously shown promising results for scaffold building (ALG and CMC) with the addition of cellulose nanofibers (NFC) for increased mechanical stability. Both ALG and CMC are negatively charged, water-soluble linear copolymers⁴⁸ and both contain carboxyl groups, which can be cross-linked with the addition of divalent cations. Ca²⁺ particles form ionic bonds with two functional groups simultaneously, forming connections between polymer chains, increasing gel rigidity.

Printing of perfusable scaffolds

The aim of this process is to 3D-print simple woodpile scaffold structures, which span over several layers and retain their shape fidelity as well as perfusability until becoming fully cross-linked. This requires even coextrusion of core and shell without crossover or retraction movements, which can interrupt the flow. Therefore, typical CAD modelling and slicing methods are less suitable. In this work, a manually designed g-code is used, and a python-based g-code generator was developed for fast g-code preparation.

The scaffolds were structured in a woodpile grid shape and built on a flat glass surface. The fabrication was performed layer-by-layer, depositing the crossing lines of each succeeding layer in an angle 90° to the previous one. Additionally, each succeeding layer was 2% narrower in the X and Y directions, ensuring continuous filament support by preceding layers. The distance between filaments (macropore size) can be precisely designed in the g-code by taking into account the outer diameter of the extruded filament (0.8 mm) and the distance between gridlines (3 mm).

Scaffolds were required to fulfill key inclusion criteria for further consideration. First, scaffolds with at least 4 layers in height were required to retain their structural integrity and geometry (e.g., macropore size) during printing, to be eligible for further development. Second, scaffolds needed to remain perfusable (stable microchannels) even after being incubated for 7 days in cell culture media at 37 °C. At appropriate time intervals (1, 2, 5, and 7 days) scaffolds were taken out of the culture media and tested to see if they were still perfusable. In **Figure 4A**, the cross-section of a freshly printed and post-processed scaffold displays a clearly visible hollow channel inside the filament. In **Figure 4B**, it is clear that even after 72 h incubation in cell culture media at 37 °C, the filament retains the hollow structure through the entire scaffold length.

Several formulations were printable, remained structurally stable, preserved the printed geometry, and remained perfusable; however, a single one was chosen for further testing (i.e., 3 wt.% ALG + 3 wt.% CMC + 1.5 wt.% NFC), which allowed printing of perfusable scaffolds with up to 10 layers. The printing process with the custom nozzle is shown in **Figure 5A**. Core/shell printing was possible with less viscous formulations; however, gels with higher concentrations did not allow continuous flow through the nozzle. For primary cross-linking (core material, delivered during printing) 100 mM CaCl₂ was utilized, which adequately stabilized the continuous formation of a hollow filament, without causing gel solidification within the nozzle. Post-printing, the scaffolds were soaked in a 5 wt.% CaCl₂ solution to completely cross-link the hydrogel for long-term shape fidelity. A finished scaffold sample is pictured in **Figure 5B**. During the optimization, process of the formulation an artificial dye was used in the core solution, to allow visual evaluation and examining the quality of the extruded filament. The dye was not used for the fabrication of the final scaffolds, which were prepared for cell seeding and cultivation.

Live/dead assay

After incubation, a live/dead assay was used to visualize the ECs and distinguish between the living (green) and the dead (red) cells within the incubated scaffold. This served two main purposes: A) to determine whether the scaffolds provide a biocompatible environment to promote growth and adhesion without exhibiting harmful effects on the cell, and B) to

visualize the structural integrity of tubular structures and their internal channel system in more detail.

The results of the live/dead assay are shown in **Figure 6**. In the presence of intracellular esterases, the plasma membrane permeable Calcein-AM is converted to Calcein, emitting green fluorescence light in live cells. On the other hand, apoptotic cells are visualized by membrane impermeable propidium iodide, which fluoresces in red when intercalated in the DNA double helix. Live/dead images and bright-field pictures of scaffolds were combined to help visualize the cells inside the hollow channels. The staining solution was injected, and the assay performed directly in the 3D printed scaffolds after scaffold-cell incubation for 48 h.

It should be noted that a relatively small seeding density of ECs was used (340,000 cells/mL), as this study served only as a proof-of-concept for core/shell printing of perfusable scaffolds. The most significant conclusion of the live/dead assay is that even after 48 h, no dead cells (red) were observed, proving that neither the scaffold material itself, nor its degradation products exhibited toxic effects. Furthermore, the ECs did in fact adhere and remain attached inside the scaffolds and seemed to form evenly distributed agglomerates when grown inside the channels. This suggests that the described fabrication method and scaffold formulation provide a suitable framework for building in vivo, relevant, tubular tissue morphologies. Besides mimicking cell-ECM interactions and tight cell-cell communication in all three spatial dimensions, complex tissue engineering also requires constant cell exposure to fresh medium to sustain their viability. This in turn can be achieved by a dense channel network under continuous perfusion, which warrants further investigation in future work, and will require optimizing material and growth parameters to facilitate long-term tissue engineering of vasculature.

FIGURE AND TABLE LEGENDS:

Figure 1: Core/shell nozzle prototype. (A) The overall design and the main components of the nozzle body prototype are shown. The nozzle is completed by inserting a blunt-end G27 needle through the top. The top and bottom needle holders immobilize and realign the needle with the nozzle axis, ensuring that the tip extends from the nozzle through the center. To connect the nozzle with “shell” material extruded from the secondary syringe, tubing with a luer-lock connector is attached to the lateral input. From here, the material is forwarded to the nozzle through a narrow channel. The fabrication of the mentioned channel requires drilling in two positions, producing holes that need to be capped after manufacturing). (B) Shown is a close-up of the nozzle with an inserted G27 needle, extending out of the nozzle.

Figure 2: Final core/shell set-up. (A) Shown is the completed core/shell nozzle with correctly attached syringes containing the hydrogel (right), building the “shell” and cross-linking solution (left) extruded as the “core”. (B) Shown is the core/shell set-up installed into the Vitaprint system with two extruders.

Figure 3: G-code of the tubular scaffold. Here a screenshot of the printer software is shown, specifically the path preview (A) and raw g-code of the first layer (B). The g-code is a set of instructions with target coordinates in absolute spatial directions (X, Y, Z), as well as extrusion (A,B) in relative directions. The G command determines the type of instruction, whereas G1

represents linear movement towards the target coordinates and G92 determines the initial starting position. In addition, the feed-rate of following commands is determined with instruction F in mm/min.

Figure 4: Cross-section of a scaffold strand with a hollow interior. (A) Shown is the cross-section slice of the freshly printed and post-processed scaffold. (B) Shown is the cross-sectional slice of the scaffold after being incubated in cell culture media for 72 h. While the nozzle shape defines the extrusion of a tube with a round cross-section, the filament appears to be somewhat flattened on deposition. The internal channel, however, stays intact and retains its form during incubation.

Figure 5: Core/shell printing of scaffolds. Here, fabrication (A) of a three-layered hollow-tube scaffold and its final form (B) are shown. For improved visualization, the cross-linking solution in the core was stained with a red dye. The formulation exhibits sufficient mechanical stability to retain scaffold stability, even if thicker structures (up to 10 layers, data not shown) are fabricated. The outer dimensions of the final structure were approximately 27 mm x 27 mm x 3.5 mm.

Figure 6: Live/dead assay performed directly in the scaffolds. A suspension of HUVECs was injected into the inner scaffold channel, incubated for 48 h, and treated with live/dead dye. Viable HUVECs emit green fluorescence light, which is represented in the bright spots of the image. Dead cells emit green fluorescence light; however, none are visible in the observed scaffold. The distribution of the cells also signifies the shape and retained perfusion capabilities of the channels. To a minor extent, the live/dead assay solution also stained the scaffolding material, producing light fluorescence under the microscope.

DISCUSSION:

Nozzle design

Using the developed core/shell nozzle, integrated into a two-extruder Vitaprint system, hollow, tubular scaffolds were fabricated in a single-step process. To achieve an even thickness of the tube wall through most of the prepared scaffolds, the needle needs to be positioned centrally on the axis of the outer extrusion ring. Standard gauge needles often exhibit a slight, yet significant eccentricity off the axis. Thus, the nozzle body was designed to hold the needle in two places, once at the top (fixing the hub) and once before the final core/shell chamber (fixing the cannula itself), correcting its axial alignment. The precision of the axial alignment increases with the distance between the fixation point. There is, however, a tradeoff between needle length and available nozzle chamber volume. To improve functionality of the set-up further, certain modifications of the nozzle can be implemented: A) a nozzle mount with improved stability, B) additional nozzles for a wider range of needle compatibility, C) a precise adjustment mechanism for needle to nozzle positioning, and D) integrating additional inputs and microfluidic devices for on the fly material preparation.

Hydrogel optimization

To determine the optimal ALG:CMC ratio, several material iterations were evaluated. Generally, core/shell printing with concentrations above 3 wt.% of both components was rendered impossible, because it did not allow for a continuous hydrogel flow or resulted in

clogging of the nozzle. Specifically, ALG concentration above 3 wt.% increased the viscosity excessively and resulted in nozzle clogging, while lower ALG concentrations and higher CMC (>3 wt.%) concentrations slowed down cross-linking times and thus failed to provide sufficient structural support of the scaffold. Core/shell printing was possible with less viscous formulations; however, extruded gel viscosity must be sufficient to sustain long term shape fidelity. In the end, a 1:1 ALG:CMC ratio was proven to be the most suitable choice which confirms a previous study by Maver et al.⁴⁹. The addition of NFC significantly improved printability and structural rigidity of core/shell printed scaffolds but had no significant effect on cross-linking properties of the material.

Custom applications, optimized for specific cell types and experimental set-ups will require well-tailored scaffolding materials, which will vary in composition and cross-linking mechanisms. The method described in this work is based on an alginate-cellulose mixed polymer solution, which is cross-linked ionically using Ca^{2+} ions. Alginate itself is a linear polymer of blocks of (1,4)-linked β -D-mannuronate (M) and α -L-guluronate (G) residues that can be reversibly ionically crosslinked by application of Ca^{2+} and other divalent cations such as Sr^{2+} , Br^{2+} , Mg^{2+} . Nevertheless, the most widely used ion for cross-linking of alginate remains Ca^{2+} in the form of CaCl_2 . Ca^{2+} can also be used in the form of CaSO_4 or CaCO_3 ; however, the low solubility of CaSO_4 relative to CaCl_2 means slower gelation. CaCO_3 yields even slower gelation times which can result in weak and inconsistent mechanical properties.

Longer gelation times typically produce a more homogenous construct, however, certain applications, such as core/shell printing requires fast gelation rates⁵⁰. Mg^{2+} ions also induce gelation; however, their cross-linking efficiency is about 5x–10x lower, compared to Ca^{2+} , with cross-linking times of 2–3 h. In addition, magnesium ions are more selective towards guluronic units, hence the cross-linking depends more on the chemical composition of the ALG⁵¹. In this case, a fast gelation rate is essential to ensure continuous hollow channel formation before the hollow structure can collapse. CaCl_2 yields the fastest gelation rate, which is crucial for the direct deposition of hollow filaments. 100 mM CaCl_2 was utilized, which adequately stabilized the continuous formation of a hollow filament without causing gel solidification within the nozzle.

Printing and post-processing of scaffolds

The following steps should be considered during this portion of the process, including 1) ensuring that all solutions and materials including the 3D bioprinter are properly sterilized before printing. 2) When preparing the hydrogel, homogeneity of the material is crucial for continuous printing. Introduction of impurities or air bubbles should be avoided, as they can clog the nozzle and/or disrupt the extrusion. 3) The syringes should be properly connected to the core/shell nozzle via the luer-lock mechanism and correctly inserted in the extruder mounts as seen in **Figure 2A,B**. 4) Before printing a complex structure, it is recommended to pre-extrude a small portion of the gel and cross-linking solution to clear the excess air bubbles in the core/shell nozzle and ensure a continuous hydrogel flow. This can be incorporated directly into the g-code to improve repeatability. 5) It is helpful to add a skirt surrounding the scaffold to ensure the laying of a homogenous hollow filament before the printing of the scaffold itself starts.

Additionally, 6) to improve adhesion between the printing filament and substrate, it is

recommended to use a flat surface with good adhesion (i.e., a glass slide or Petri dish). 7) The extrusion nozzle should not be in direct contact with the substrate to allow for uninterrupted flow of the hydrogel. The initial distance will strongly impact the quality of the print, but thickness of the extruded filament is a good approximation of the initial setting. 8) The starting printing height in the g-code should be adjusted according to individual needs. After the printing parameters are optimized, the scaffold g-code should be imported into Planet CNC software and the printing process started as described in the protocol. 9) To control and optimize hydrogel flow with the intention to print optimal scaffolds, both formulation composition and printing parameters should be varied (i.e., printing speed, extrusion pressure, printing temperature, distance between the substrate and extrusion nozzle, layer height, scaffold size, etc.).

In general, higher flow rates are required to print formulations with higher viscosity. As mentioned, all hydrogel formulations, which are suitable for immediate chemical cross-linking, allow for one-step fabrication of hollow tubes and may be used with the described core/shell set-up. The printing and cross-linking mechanisms need to be optimized accordingly. After printing, all scaffolds were post-processed by secondary cross-linking with 5 wt.% CaCl₂ solution, which assured complete cross-linking of the ALG-CMC component and sterilized from both sides under a UV light for at least 30 min. It should be ensured to completely engulf the scaffold with the cross-linking solution and incubate for long enough to complete the cross-linking process. Post-processing will differ based on the material and cross-linking mechanism used, which should be considered beforehand. After post-processing, scaffolds should be removed carefully from the substrate, transferred to cell culture media, and incubated in a controlled atmosphere for at least 24 h before cell seeding. Using a colorless medium will improve visibility of the cell suspension during injection into the scaffolds.

Live/dead assay

The live/dead solution should be prepared directly before conducting the assay and kept in the dark before conducting the assay, as it contains fluorescence dyes that are prone to bleaching. After the desired incubation time, the cell culture media should be carefully discarded surrounding the scaffolds and rinsed with PBS. Ideally, the same entry point should be used for cell seeding followed by the live/dead assay being injected into the scaffolds.

Importance of results

Both ALG and CMC have been already used to promote angiogenesis in vitro. Based on its ECM-mimetic features, physical cross-linking, and biocompatibility, ALG has been commonly employed as a component for delivery and controlled release of angiogenic growth factors (e.g., bFGF, HGF, VEGF164, and Ang-1*respectively)⁵²⁻⁵⁴. Furthermore, in combination with gelatine, CMC has also been used for encapsulating vascular endothelial cells due its rapidly cross-linking capabilities under physiological conditions⁵⁵. NFC were added to further increase the mechanical stability and shape fidelity of scaffolds. It should be emphasized that the objective was not to enhance the vascularization but to demonstrate the possibility of producing perfusable, hollow ALG-CMC scaffolds, printed in core/shell fashion, which also facilitates the attachment and proliferation of HUVECs. The choice of using an ALG-CMC mixture was based on findings of commonly used, easily accessible, and biocompatible base materials that could enable core/shell printing of hollow channels. Many other materials may

be more viable options for enhancing angiogenesis; however, some are not suitable for core/shell printing, as they do not facilitate rapid gelation/cross-linking, which is crucial in this approach.

ACKNOWLEDGMENTS:

The authors would like to acknowledge the financial support for this project received from the Slovenian Research Agency (grant numbers: P3-0036, and I0-0029), and the Ministry of Science, Education and Sport (grant number: 5442-1/2018/59).

DISCLOSURES:

The authors declare that they have no competing financial interests.

REFERENCES:

- 1 Langer, R., Vacanti, J. Advances in tissue engineering. *Journal of pediatric surgery*. **51** (1), 8-12 (2016).
- 2 Atala, A., Kasper, F. K., Mikos, A. G. Engineering complex tissues. *Science Translational Medicine*. **4** (160), 160rv112-160rv112 (2012).
- 3 Khademhosseini, A., Vacanti, J. P., Langer, R. Progress in tissue engineering. *Scientific American*. **300** (5), 64-71 (2009).
- 4 Wobma, H., Vunjak-Novakovic, G. Tissue Engineering and Regenerative Medicine 2015: A Year in Review. *Tissue Engineering Part B: Reviews*. **22** (2), 101-113 (2016).
- 5 Park, K. M., Shin, Y. M., Kim, K., Shin, H. Tissue Engineering and Regenerative Medicine 2017: A Year in Review. *Tissue Engineering Part B: Reviews*. **24** (5), 327-344 (2018).
- 6 Mattei, G., Giusti, S., Ahluwalia, A. Design criteria for generating physiologically relevant in vitro models in bioreactors. *Processes*. **2** (3), 548-569 (2014).
- 7 Elliott, N. T., Yuan, F. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. *Journal of Pharmaceutical Sciences*. **100** (1), 59-74 (2011).
- 8 Breslin, S., O'Driscoll, L. Three-dimensional cell culture: the missing link in drug discovery. *Drug Discovery Today*. **18** (5-6), 240-249 (2013).
- 9 Edmondson, R., Broglie, J. J., Adcock, A. F., Yang, L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. *Assay and Drug Development Technologies*. **12** (4), 207-218 (2014).
- 10 Horvath, P. *et al.* Screening out irrelevant cell-based models of disease. *Nature Reviews Drug Discovery*. **15** (11), 751-769 (2016).
- 11 Di Nardo, P., Minieri, M., Ahluwalia, A. in *Stem Cell Engineering*. 41-59 (Springer, 2011).
- 12 Lee, K., Silva, E. A., Mooney, D. J. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. *Journal of the Royal Society Interface*. **8** (55), 153-170 (2011).
- 13 Tayalia, P., Mooney, D. J. Controlled growth factor delivery for tissue engineering. *Advanced Materials*. **21** (32-33), 3269-3285 (2009).
- 14 Caddeo, S., Boffito, M., Sartori, S. Tissue Engineering Approaches in the Design of Healthy and Pathological In Vitro Tissue Models. *Frontiers in Bioengineering and Biotechnology*. **5**, 40 (2017).
- 15 Chang, H.-I., Wang, Y. in *Regenerative medicine and tissue engineering-cells and biomaterials*. (InTech, 2011).

655 16 Rice, J. J. *et al.* Engineering the regenerative microenvironment with biomaterials.
656 *Advanced Healthcare Materials*. **2** (1), 57-71 (2013).

657 17 Khademhosseini, A., Langer, R. A decade of progress in tissue engineering. *Nature*
658 *Protocols*. **11** (10), 1775-1781 (2016).

659 18 Yu, Y., Alkhawaji, A., Ding, Y., Mei, J. Decellularized scaffolds in regenerative medicine.
660 *Oncotarget*. **7** (36), 58671-58683 (2016).

661 19 Tibbitt, M. W., Anseth, K. S. Hydrogels as extracellular matrix mimics for 3D cell
662 culture. *Biotechnology and bioengineering*. **103** (4), 655-663 (2009).

663 20 Lovett, M., Lee, K., Edwards, A., Kaplan, D. L. Vascularization strategies for tissue
664 engineering. *Tissue Engineering Part B: Reviews*. **15** (3), 353-370 (2009).

665 21 Rouwkema, J., Rivron, N. C., van Blitterswijk, C. A. Vascularization in tissue
666 engineering. *Trends in Biotechnology*. **26** (8), 434-441 (2008).

667 22 Bae, H. *et al.* Building vascular networks. *Sci Transl Med*. **4** (160), 160ps123, (2012).

668 23 Štumberger, G. & Vihar, B. Freeform Perfusable Microfluidics Embedded in Hydrogel
669 Matrices. *Materials*. **11** (12), 2529 (2018).

670 24 Ibrahim, M., Richardson, M. K. Beyond organoids: In vitro vasculogenesis and
671 angiogenesis using cells from mammals and zebrafish. *Reproductive Toxicology*. **73**
672 292-311, (2017).

673 25 Sorrell, J. M., Baber, M. A., Caplan, A. I. Influence of adult mesenchymal stem cells on
674 in vitro vascular formation. *Tissue Engineering Part A*. **15** (7), 1751-1761 (2009).

675 26 Davies, N. H., Schmidt, C., Bezuidenhout, D., Zilla, P. Sustaining neovascularization of
676 a scaffold through staged release of vascular endothelial growth factor-A and platelet-
677 derived growth factor-BB. *Tissue Engineering Part A*. **18** (1-2), 26-34 (2012).

678 27 Li, X., He, J., Zhang, W., Jiang, N., Li, D. Additive manufacturing of biomedical
679 constructs with biomimetic structural organizations. *Materials*. **9** (11), 909, (2016).

680 28 Murphy, S. V. & Atala, A. 3D bioprinting of tissues and organs. *Nature Biotechnology*.
681 **32** (8), 773 (2014).

682 29 Hasan, A. *et al.* Microfluidic techniques for development of 3D vascularized tissue.
683 *Biomaterials*. **35** (26), 7308-7325 (2014).

684 30 Kolesky, D. B. *et al.* 3D bioprinting of vascularized, heterogeneous cell-laden tissue
685 constructs. *Advanced Materials*. **26** (19), 3124-3130 (2014).

686 31 Huang, Y., Zhang, X. F., Gao, G., Yonezawa, T., Cui, X. 3D bioprinting and the current
687 applications in tissue engineering. *Biotechnology Journal*. (2017).

688 32 Wang, X. *et al.* 3D bioprinting technologies for hard tissue and organ engineering.
689 *Materials*. **9** (10), 802 (2016).

690 33 Hinton, T. J. *et al.* Three-dimensional printing of complex biological structures by
691 freeform reversible embedding of suspended hydrogels. *Science Advances*. **1** (9),
692 e1500758 (2015).

693 34 Rocca, M., Fragasso, A., Liu, W., Heinrich, M. A., Zhang, Y. S. Embedded Multimaterial
694 Extrusion Bioprinting. *SLAS Technology*. **23** (2), 154-163 (2018).

695 35 Hinton, T. J. *et al.* Three-dimensional printing of complex biological structures by
696 freeform reversible embedding of suspended hydrogels. *Science Advances*. **1** (9),
697 e1500758 (2015).

698 36 Huang, S., Yang, Y., Yang, Q., Zhao, Q., Ye, X. Engineered circulatory scaffolds for
699 building cardiac tissue. *Journal of Thoracic Disease*. **10** (Suppl 20), S2312-s2328 (2018).

700 37 Hoch, E., Tovar, G. E. & Borchers, K. Bioprinting of artificial blood vessels: current
701 approaches towards a demanding goal. *European Journal of Cardiothoracic Surgery*.
702 **46** (5), 767-778 (2014).

703 38 Yeo, M., Lee, J. S., Chun, W., Kim, G. H. An Innovative Collagen-Based Cell-Printing
704 Method for Obtaining Human Adipose Stem Cell-Laden Structures Consisting of Core-
705 Sheath Structures for Tissue Engineering. *Biomacromolecules*. **17** (4), 1365-1375
706 (2016).

707 39 Liu, W. *et al.* Coaxial extrusion bioprinting of 3D microfibrinous constructs with cell-
708 favorable gelatin methacryloyl microenvironments. *Biofabrication*. **10** (2), 024102
709 (2018).

710 40 Gao, Q., He, Y., Fu, J. Z., Liu, A., Ma, L. Coaxial nozzle-assisted 3D bioprinting with built-
711 in microchannels for nutrients delivery. *Biomaterials*. **61**, 203-215 (2015).

712 41 Akkineni, A. R., Ahlfeld, T., Lode, A., Gelinsky, M. A versatile method for combining
713 different biopolymers in a core/shell fashion by 3D plotting to achieve mechanically
714 robust constructs. *Biofabrication*. **8** (4), 045001 (2016).

715 42 Colosi, C. *et al.* Microfluidic Bioprinting of Heterogeneous 3D Tissue Constructs Using
716 Low-Viscosity Bioink. *Advanced Materials*. **28** (4), 677-684 (2016).

717 43 Kim, G., Ahn, S., Kim, Y., Cho, Y., Chun, W. Coaxial structured collagen–alginate
718 scaffolds: fabrication, physical properties, and biomedical application for skin tissue
719 regeneration. *Journal of Materials Chemistry*. **21** (17), 6165-6172 (2011).

720 44 Luo, Y., Lode, A., Gelinsky, M. Direct plotting of three-dimensional hollow fiber
721 scaffolds based on concentrated alginate pastes for tissue engineering. *Advanced*
722 *Healthcare Materials*. **2** (6), 777-783 (2013).

723 45 Mistry, P. *et al.* Bioprinting Using Mechanically Robust Core-Shell Cell-Laden Hydrogel
724 Strands. *Macromolecular Bioscience*. **17** (6), (2017).

725 46 Banović, L., Vihar, B. Development of an extruder for open source 3D bioprinting.
726 *Journal of Open Hardware*. **2** (1), (2018).

727 47 HUV-EC-C [HUVEC] (ATCC® CRL-1730™) *Homo sapiens umbilical vein*,
728 <[http://www.lgcstandards-atcc.org/products/all/CRL-](http://www.lgcstandards-atcc.org/products/all/CRL-1730.aspx?geo_country=si#documentation)
729 [1730.aspx?geo_country=si#documentation](http://www.lgcstandards-atcc.org/products/all/CRL-1730.aspx?geo_country=si#documentation)> (March 2019).

730 48 Habib, A., Sathish, V., Mallik, S., Khoda, B. 3D printability of alginate-carboxymethyl
731 cellulose hydrogel. *Materials*. **11** (3), 454 (2018).

732 49 Maver, T. *et al.* Combining 3D printing and electrospinning for preparation of pain-
733 relieving wound-dressing materials. *Journal of Sol-Gel Science and Technology*. 1-16
734 (2018).


735 50 Kuo, C. K., Ma, P. X. Ionically crosslinked alginate hydrogels as scaffolds for tissue
736 engineering: Part 1. Structure, gelation rate and mechanical properties. *Biomaterials*.
737 **22** (6), 511-521 (2001).



738 51 Topuz, F., Henke, A., Richtering, W., Groll, J. Magnesium ions and alginate do form
739 hydrogels: a rheological study. *Soft Matter*. **8** (18), 4877-4881 (2012).



740 52 Perets, A. *et al.* Enhancing the vascularization of three-dimensional porous alginate
741 scaffolds by incorporating controlled release basic fibroblast growth factor
742 microspheres. *Journal of Biomedical Materials Research Part A*. **65** (4), 489-497 (2003).


743 53 Ruvinov, E., Leor, J., Cohen, S. The effects of controlled HGF delivery from an affinity-
744 binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb
745 ischemia model. *Biomaterials*. **31** (16), 4573-4582 (2010).

746 54 Peirce, S. M., Price, R. J., Skalak, T. C. Spatial and temporal control of angiogenesis and
747 arterialization using focal applications of VEGF164 and Ang-1. *American Journal of*
748 *Physiology-Heart and Circulatory Physiology*. **286** (3), H918-925 (2004).
749 55 Kageyama, T. *et al.* In situ cross-linkable gelatin-CMC hydrogels designed for rapid
750 engineering of perfusable vasculatures. *ACS Biomaterials Science & Engineering*. **2** (6),
751 1059-1066 (2016).
752











```

1: %
2: G92 X-4 Y-4 F500
3: G1 X30 Y-4 A[#<_A>+0.1] B[#<_B>+0.39]
4: G1 X30 Y30 A[#<_A>+0.1] B[#<_B>+0.39]
5: G1 X-4 Y30 A[#<_A>+0.1] B[#<_B>+0.39]
6: G1 X-4 Y-4 A[#<_A>+0.1] B[#<_B>+0.39]
7:
8: G1 X0 Y0 A[#<_A>+0.1] B[#<_B>+0.39] F500
9: G1 X0 Y26 A[#<_A>+0.1] B[#<_B>+0.39]
10: G1 X3
11: G1 X3 Y0 A[#<_A>+0.1] B[#<_B>+0.39]
12: G1 X6
13: G1 X6 Y26 A[#<_A>+0.1] B[#<_B>+0.39]
14: G1 X9
15: G1 X9 Y0 A[#<_A>+0.1] B[#<_B>+0.39]
16: G1 X12
17: G1 X12 Y26 A[#<_A>+0.1] B[#<_B>+0.39]
18: G1 X15
19: G1 X15 Y0 A[#<_A>+0.1] B[#<_B>+0.39]
20: G1 X18
21: G1 X18 Y26 A[#<_A>+0.1] B[#<_B>+0.39]
22: G1 X21
23: G1 X21 Y0 A[#<_A>+0.1] B[#<_B>+0.39]
24: G1 X24
25: G1 X24 Y25.5 A[#<_A>+0.1] B[#<_B>+0.39]
26:
27: Z1
28:
29: G1 X0.5 Y25.5 A[#<_A>+0.1] B[#<_B>+0.39]
30: G1 Y22
31: G1 X23.5 Y22 A[#<_A>+0.1] B[#<_B>+0.39]
32: G1 Y19
33: G1 X0.5 Y19 A[#<_A>+0.1] B[#<_B>+0.39]
34: G1 Y16
35: G1 X23.5 Y16 A[#<_A>+0.1] B[#<_B>+0.39]
36: G1 Y13
37: G1 X0.5 Y13 A[#<_A>+0.1] B[#<_B>+0.39]
38: G1 Y10
39: G1 X23.5 Y10 A[#<_A>+0.1] B[#<_B>+0.39]
40: G1 Y7
41: G1 X0.5 Y7 A[#<_A>+0.1] B[#<_B>+0.39]
42: G1 Y4
43: G1 X23.5 Y4 A[#<_A>+0.1] B[#<_B>+0.39]
44: G1 Y1
45: G1 X0 Y1 A[#<_A>+0.1] B[#<_B>+0.39]

```



Name of Reagent/ Equipment

- Alginate acid sodium salt
- ATCC HUV-EC-C [HUVEC]
- Axiovert 40 inverted optical microscope
- Calcium chloride
- Cellulose nanofibrils suspension (NFC, 3% (w/v))
- ELGA Purelab water purification system
- EVOS FL Cell Imaging System
- Gibco Advanced Dulbecco’s modified Eagle’s medium (Advance DMEM)
- Gibco Dulbecco’s modified Eagle’s medium (DMEM)
- Gibco Fetal Bovine Serum (FBS), qualified
- Hypodermic Sterican needle
- L-glutamine
- Live/Dead Cell Double Staining Kit
- Nunc EasYFlask cell culture flasks
- Omnifix syringe

Penicillin G sodium salt

Phosphate buffered saline

Sodium carboxymethyl cellulose

Streptomycin sulfate salt

Ultra-pure water

VitaPrint 3D bio-printer

Company

Sigma-Aldrich (Germany)

LGC Standards (UK)

Carl Zeiss Microscopy GmbH (Germany)

Sigma-Aldrich (Germany)

The Process Development Center, University of Maine (Maine, USA)

Veolia Water Technologies (UK)

ThermoFisher Scientific Inc. (Germany)

ThermoFisher Scientific Inc. (Germany)

ThermoFisher Scientific Inc. (Germany)

ThermoFisher Scientific Inc. (Germany)

B. Braun Melsungen AG (Germany)

Sigma-Aldrich (Germany)

Sigma-Aldrich (Germany)

ThermoFisher Scientific Inc. (Germany)

B. Braun Melsungen AG (Germany)

Sigma-Aldrich (Germany)

Sigma-Aldrich (Germany)

Sigma-Aldrich (Germany)

Sigma-Aldrich (Germany)

Veolia Water Technologies (UK)

IRNAS (Slovenia)

| Catalog Number | Comments/Description |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 180947 | powder; Mw ~80,000 |
| ATCC-CRL-1730 | Endothelial Cell Growth Supplement (ECGS) and unidentified factors for three contrasting techniques in one objective – e.g. brightfield, phase contrast |
| C1016 | anhydrous; granular; ≤ 7.0 mm; $\geq 93.0\%$ nominal fiber width of 50 nm; lengths of up to several hundred microns |
| AMF4300 | a fully integrated, digital, inverted imaging system for four-color fluorescence |
| 12491015 | high glucose; no glutamine; phenol red |
| 21063029 | high glucose; L-glutamine; HEPES; no phenol red |
| 10270106 | FBS origin: Brazil; 5 % (w/v) FBS |
| 9180117 | 0.40 x 25mm, 27G x 1" |
| G3126 | <i>ReagentPlus</i> [®] , $\geq 99\%$ (HPLC) |
| 4511 | contains calcein-AM and propidium iodide (PI) solutions; suitable for fluorescence |
| 156367 | Nunclon Delta certified for monolayer formation, cloning efficiency, no |
| 4617053V | 5 mL Luer Lock |

| | |
|--------|-------------------------------------------------------------------------|
| P3032 | powder; BioReagent; suitable for cell culture |
| P4417 | tablet; one tablet dissolved in 200 mL of deionized water yields 0.01 M |
| 419338 | powder; average Mw ~700,000 |
| S9137 | powder; BioReagent; suitable for cell culture |
| | 18.2 mΩ cm at 25°C |

om bovine pituitary, hypothalamus or whole brain extracts are mitogenic for this line; the cells have a life expectancy of 50 to 60 population

ontrast and PlasDIC

S

science and transmitted-light applications

uorescence

n-cytotoxic, non-pyrogenic, and sterility; filter caps; culture area of 25 cm²

phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4, at 25 °C

on doublings.

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

CORE/SHELL PRINTING SCAFFOLDS FOR TISSUE ENGINEERING
OF TUBULAR STRUCTURES

Author(s):

MARCO MILOJEVIĆ, BOŠTJAN VIHAR, LUKA BANDUČ, MIHAIL MIŠKO,
LIDIJA GRADIŠNIK, TANJA ZIDARIČ, UROŠ MAVER

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

612542.6 For questions, please contact us at submissions@jove.com or +1.617.945.9051.

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

| | | |
|--------------|-------------------------------------------------------------------------------------|----------------------|
| Name: | MARKO MILOJEVIĆ | |
| Department: | INSTITUTE OF BIOMEDICAL SCIENCES | |
| Institution: | FACULTY OF MEDICINE, UNIVERSITY OF DALHOUSIE | |
| Title: | / | |
| Signature: |  | Date: 5. March, 2019 |

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

612542.6 For questions, please contact us at submissions@jove.com or +1.617.945.9051.

Response to editorial comments:

We thank the editorial board for their comments and guidelines. We have tried to revise the manuscript as you suggest to the best of our abilities, which hopefully resulted in a higher quality manuscript.

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

We have revised the language of the manuscript as you suggest and have hopefully eliminated the errors.

2. Please avoid long steps/notes (more than 4 lines).

This has been changed.

3. Please do not highlight notes for filming.

Noted, has been changed.

4. The highlighted protocol steps are over the 2.75 page limit (including headings and spacing). Please highlight fewer steps for filming.

We have done so, should be o know.

5. JoVE cannot publish manuscripts containing commercial language. This includes company names of an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents.

We have corrected this, should be o know. Please let us know if you still find any unwanted mentions.

6. Please use h, min, s for time units.

Noted, has been changed.

7. Please do not use lists in Representative Results or Discussion (lines 368-382, 443-446, 527-530, 570-596).

Noted, the formatting has been changed.